What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
The scientist’s investigation covers issues in Immunology, Ipilimumab, Immune system, Immunotherapy and Melanoma.
His Immunology research incorporates elements of Cytotoxic T cell, Cancer and Cancer research.
The concepts of his Ipilimumab study are interwoven with issues in Nivolumab and Antigen.
The Nivolumab study which covers Renal cell carcinoma that intersects with Urology.
The Immune system study combines topics in areas such as Combined Modality Therapy, Radiation therapy and Antibody.
His research integrates issues of Oncology and Gut microbiome in his study of Immunotherapy.
His most cited work include:
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (3172 citations)
- The future of immune checkpoint therapy (2293 citations)
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. (1544 citations)
What are the main themes of his work throughout his whole career to date?
Padmanee Sharma spends much of his time researching Internal medicine, Oncology, Ipilimumab, Immunology and Cancer research.
His work on Nivolumab, Clinical trial and Phases of clinical research as part of general Internal medicine research is frequently linked to In patient, thereby connecting diverse disciplines of science.
His study explores the link between Nivolumab and topics such as Renal cell carcinoma that cross with problems in Carcinoma.
His Ipilimumab study incorporates themes from Monoclonal antibody, Cohort and Pharmacology.
The various areas that Padmanee Sharma examines in his Immunology study include Cancer, Cytotoxic T cell and Melanoma.
His research on Cancer research also deals with topics like
- Bioinformatics most often made with reference to Immune system,
- Blockade, which have a strong connection to CTLA-4.
He most often published in these fields:
- Internal medicine (46.13%)
- Oncology (40.65%)
- Ipilimumab (31.29%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (46.13%)
- Oncology (40.65%)
- Cancer research (27.74%)
In recent papers he was focusing on the following fields of study:
Padmanee Sharma mainly focuses on Internal medicine, Oncology, Cancer research, Immune checkpoint and Nivolumab.
His work deals with themes such as Clinical endpoint, Clinical trial and Ipilimumab, Tremelimumab, which intersect with Oncology.
His Cancer research study integrates concerns from other disciplines, such as Tumor microenvironment, T cell, Immune system and Immunotherapy.
His Immune system research incorporates themes from Cancer and Lung cancer.
His Immune checkpoint study also includes fields such as
- Adverse effect and related Myocarditis and Immunology,
- Antibody together with FOXP3.
His Atezolizumab study in the realm of Nivolumab interacts with subjects such as Azacitidine.
Between 2018 and 2021, his most popular works were:
- B cells and tertiary lymphoid structures promote immunotherapy response (330 citations)
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (140 citations)
- Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. (115 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Cancer research, Immune checkpoint, Internal medicine, Nivolumab and Ipilimumab.
Padmanee Sharma combines subjects such as Tumor microenvironment, T cell, CD8, Immune system and Immunotherapy with his study of Cancer research.
His Immunotherapy research integrates issues from Stromal cell and Melanoma.
His biological study spans a wide range of topics, including Prostate cancer and Tremelimumab.
His biological study deals with issues like Oncology, which deal with fields such as Clinical endpoint and Adverse effect.
His research in Nivolumab intersects with topics in Gastroenterology, Renal cell carcinoma, Clear cell renal cell carcinoma and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
